

List of Essential Cancer Medicines the ATOM Coalition will focus on in 2023–24

	16	5
On patent	<ul style="list-style-type: none"> • osimertinib • palbociclib • ribociclib • abemaciclib • zanubrutinib • pembrolizumab* • nivolumab* • atezolizumab • durvalumab • tislelizumab • daratumumab • rituximab–subcutaneous • trastuzumab–subcutaneous • dabrafenib+trametinib • vemurafenib+cobimetinib • encorafenib+binimetinib <p><i>*Anti- PD1/PD-L1 immune checkpoints inhibitors</i></p>	<ul style="list-style-type: none"> • enzalutamide • nilotinib • pembrolizumab • nivolumab • ibrutinib
Off patent		<p>5 breast cancer medicines from the following MEAG approved list.</p> <ul style="list-style-type: none"> • capecitabine • carboplatin • cyclophosphamide • docetaxel • doxorubicin • fluorouracil • methotrexate • paclitaxel • trastuzumab • Aromatase inhibitors* • tamoxifen
	Not on EML	On EML

